Akebia Therapeutics Inc. (AKBA)’s stock is trading at $1.67 at the moment marking a fall of -2.05% from the last session close. As of this writing, shares are priced at -8.97% less than their 52-week high of $1.84, and 241.77% over their 52-week low of $0.49.
The 200-day Simple moving average is often placed more emphasis on by traders because of daily price changes. Investors will use the SMA-200 in different situations in trading activity as a key indicator to determine their support and resistance levels, and at the moment, AKBA’s SMA-200 is $1.2321.
Further, it is important to consider AKBA stock ratios, particularly its price-to-sales ratio over the past twelve months, which stands at 1.63.
How does Akebia Therapeutics Inc. (AKBA) stock rate among analysts? Buy, sell, or hold?
The key to trading is to concentrate on the future rather than on the past. During uncertain times, it can be hard to make decisions. The analysts who understand how a market works are usually the most accurate at forecasting its future. Currently, there are 4 brokerage firms that recommend the stock as a Strong Buy. The ratings are commonly aggregated into a single number between 1 and 5. Buy or strong buy is scored 5, outperform is scored 4, hold is scored 3, underperform is scored 2 and strong sell is 1. Using a scale of 1-5, the current average recommendation is 4.50 in simple terms.
Akebia Therapeutics Inc. (AKBA): Earnings History
If we examine Akebia Therapeutics Inc.’s recent earnings history, in the last quarter ended on 9/29/2023, it posted adjusted earnings per share of -$0.08, slashing the consensus of -$0.08. In other words, it beat the consensus by $0, resulting in a 0.00% surprise. In the 3 months period before the previous quarter which was closed on 9/29/2023, the stock recorded adjusted earnings per share of -$0.08 in contrast with the Outlook of -$0.08. That was a difference of $0 and a surprise of 0.00%.
Akebia Therapeutics Inc. (AKBA): Earnings History
Most analysts expect public companies to report earnings and revenue in line with their projections, but sometimes these figures vary from what they actually expected. In the current quarter, the company had earnings predictions made by 2 different analysts, who are expecting earnings to fall in between the range of -0.03 and -0.06 with an average Earnings Estimate of -0.04 which is in contrast with the last year earnings estimate of -0.04 and also replicates unch growth rate year over year.
Akebia Therapeutics Inc. (NASDAQ: AKBA) Ownership Details
I will give a breakdown of the key shareholders in Akebia Therapeutics Inc. (AKBA). Recent figures show that the company’s insiders hold 2.96% of shares. A total of 100 institutional investors hold shares in the company, making 29.21% of its stock and 30.10% of its float.
Jun 29, 2023, it was reported that the Company’s largest institutional holder is Alerce Investment Management, L.P. holding total of 16.21 million shares that make 8.61% of the company’s total number of shares and are currently priced at 14.83 million.
The securities firm Vanguard Group Inc holds 7.81 million shares of AKBA, making it the second largest institutional shareholder. Taking this into account, the holding percentage comes to 4.15%, and the holding percentage of shares is valued at 7.15 million.
An overview of Akebia Therapeutics Inc.’s technicals
In order to learn about trade movements and investor behavior, it is best to analyze the short, medium, and long term technical indicators along with the average volume of a stock. A 20-day average of the stock’s daily volume suggests Akebia Therapeutics Inc. (AKBA) traded 2,120,584 shares per day, with a moving average of $1.5600 and price change of +0.1300. With the moving average of $1.4934 and a price change of +0.5900, about 2,122,218 shares changed hands on average over the past 50 days. Finally, AKBA’s 100-day average volume is 1,730,807 shares, alongside a moving average of $1.2402 and a price change of +0.7700.
